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OBJECTIVES: Acromegaly, a relatively rare chronic endocrine disorder, results 
from excessive growth hormone (GH) secretion from a pituitary adenoma. 
Information on treatment practices and burden of acromegaly is limited. This 
study focused on assessing the burden of disease based on data retrieved from a 
large series of these patients. METHODS: A retrospective chart audit was 
conducted in September 2012 in US, France Italy and Brazil. Ninety-seven 
endocrinologists completed structured case report forms for the 4 most recently-
seen acromegaly patients (N=380); those on the last choice of medical therapy ≥6 
months ‘qualified’ for this this analysis (N=335). Patient demographics, 
comorbidities, treatment history, insulin-like growth factor [IGF-1], random 
growth hormone [GH]), symptoms and health care resource utilization were 
recorded. Control of IGF-1 was defined as IGF-1≤1ULN, control of GH as GH≤2.5 
μg/L. RESULTS: Fifty-two percent of patients were males, mean age 51 years; 63% 
with controlled IGF-1; 34% with controlled IGF-1+GH. The prevalence of 
comorbidities (hypertension, diabetes, arthritis) was similar in patients with 
controlled versus uncontrolled IGF-1 and in patients with controlled versus 
uncontrolled IGF-1+GH. The rate of paresthesia was significantly lower in 
patients with controlled versus uncontrolled IGF-1 (10% vs. 23%, p=0.003) and in 
patients with controlled versus uncontrolled IGF-1+GH (9% vs. 25%, p=0.015). 
Utilization of health care resources was similar in patients with controlled 
versus uncontrolled IGF-1 except for days hospitalized, which were significantly 
higher for patients with uncontrolled IGF-1 (p<0.05). Patients with controlled IGF-
1+GH had significantly lower number of HCP visits, hospitalizations and length 
of hospitalization than those uncontrolled (p<0.01). In multivariable models 
predicting resource utilization based on biochemical control and comorbidities, 
IGF-1+GH control remained a statistically significant predictor of HCP visits, 
hospitalizations, and days hospitalized (p<0.05). CONCLUSIONS: This 
retrospective chart audit demonstrated that acromegaly patients with controlled 
IGF-1+GH have reduced symptom burden and resource utilization than 
uncontrolled patients.  
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OBJECTIVES: Hypoglycaemia is a common complication of insulin therapy and 
can impede optimal diabetes management, with implications for patients and 
health care resourcing. Many patients with Type-2 diabetes mellitus (T2DM) use 
premixed insulin regimens, but data on frequency and impact of hypoglycaemia 
in these patients are limited outside clinical trials. METHODS: A total of 3827 
insulin-treated patients in Austria, Denmark, Finland, Norway, Netherlands, 
Sweden and Switzerland were recruited, mainly via online panels, to complete 
four questionnaires at week-intervals. Data were collected on demographics and 
non-severe hypoglycaemic events (NSHE) in the preceding seven days. NSHE was 
an event with symptoms of hypoglycaemia, with or without blood glucose 
measurement (BGM), or low BGM (≤55 mg/dl) without symptoms, which the 
patient managed without assistance. Severe hypoglycaemic events (SHE) — 
defined as events requiring third-party assistance — were also reported. 
RESULTS: The 258 T2DM patients on premixed insulin reported 826 patient-
weeks. Mean insulin-treatment duration was 7 years, mean HbA1c7.9% (SD 1.6). 
Mean self-reported NSHEs were 0.52 per patient-week (SD 1.15), 33% of which 
were nocturnal (versus 23% in overall study). Mean annual frequency of SHEs 
was 0.2. Impaired awareness or unawareness of hypoglycaemia (answering 
‘usually/sometimes/never’ to question ‘can you feel when your blood sugar is 
low?’) was reported in 57% (versus 63% in overall study). Of the 36% employed, 
5% reported lost work time due to the last NSHE. Mean increase in BG test-strips 
was 3.2 over the 7 days following each NSHE. Nine percent of patients contacted 
a health care professional following a daytime, 10% following nocturnal NSHE. 
CONCLUSIONS: NSHE are common amongst premixed-insulin-treated T2DM 
patients; a third occurring at nighttime. NSHE were associated with work time 
loss and increased health care resource use, however hypoglycaemia awareness 
was low, and events not often reported to patients’ GP/specialist. The real-world 
rates — and burden — of hypoglycaemia may therefore be underestimated.  
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BACKGROUND: Self-monitoring blood glucose (SMBG) is a useful tool to optimize 
diabetes control but increases its care cost. However, there is no data about its 
usage and cost in Argentina. OBJECTIVES: To estimate, in Argentina, the number 
of strips used for SMBG at the Social Security system (SSS) and its relationship 
with the type of treatment and degree of metabolic control. METHODS: An 
observational-retrospective study employing registries from the Pharmaceutical 
College of the Province of Buenos Aires (COLFARMA, 8115 anonymized recipes of 
drugs and strips prescribed in the period February to April 2012) and from one 
organization of the SSS (OSPERYH, 681 affiliates, strips consumption plus 
laboratory data during 2010). Statistical analysis includes ANOVA, t-test, U de 
Mann-Whitney and Kruskall-Wallis. RESULTS: OSPERYH: strips were provided 
under an audit system that assesses diabetes education, type of treatment and 
degree of metabolic control. Monthly overall average consumption was 24.6±14.5 
(mean±SD) and it was strongly related to the treatment: insulin 34.5±16.6 and 
oral antidiabetic drugs (OAD) 22.5±12.6. In each group, people with HbA1c values 
< 7% consumed more strips than those above such value. COLFARMA: the overall 
average strips consumption was 97.5±70.1. The types of treatment significantly 
affect strips consumption: insulin alone 111.0±76.3, insulin+OAD 89.0±62.5, 
combined OAD 74.7±47.3 and OAD monotherapy 66.2±45.0 strips. Despite this 
consumption was almost four times larger than in OSPERYH, the treatment-
dependent consumption pattern was similar in both groups. The strips 
represent, on average, 44 and 66% of the total cost of the prescription in 
COLFARMA and OSPERHY, respectively; and vary according to the treatment 
(OSPERHY and COLFARMA): OAD monotherapy 66 and 85%; combined OAD 39% 
and 62%; insulin 28 and 53%, respectively. CONCLUSIONS: The number of strips 
increased as a function of the type of treatment and attainment of therapeutic 
goals. Prescription audit significantly decreased such consumption.  
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OBJECTIVES: Adhering to prescribed medication can be problematic for patients 
with diabetes yet there is no gold standard for measuring adherence in this 
patient population. This systematic literature review aimed to critically review 
and summarize the methods used to measure medication adherence in patients 
with diabetes in original research published between 2007-2012, and to highlight 
novel methods that are particularly relevant in assessing adherence to variable-
dosed insulin regimens. METHODS: A systematic search for articles describing 
methods to assess medication adherence in patients with type I or type II 
diabetes (on oral hypoglycemic agents, and/or insulin) was conducted using 
PubMed, EMBASE, PsychInfo, and Cochrane Databases. Two researchers 
independently screened abstracts for initial eligibility, then applied the 
inclusion/exclusion criteria to the relevant full-text articles. RESULTS: Fifty-five 
articles met the criteria for inclusion. In prospective studies, the identified 
medication adherence evaluation methods included subjective assessment 
(observer-reported and patient-reported), pill counts, Medication Event 
Monitoring System (MEMS), cell-phone real-time assessment and logbooks. 
Biochemical measurement as a proxy for adherence was also employed in some 
prospective studies. In all pharmacy claims database studies, medication 
possession ratios (MPRs), or some derivation thereof was utilized. Few 
approaches specifically addressed issues unique to assessing insulin adherence. 
However, two novel approaches (using cell-phone real-time assessment, and 
computerized logbooks) provided insight as to timing and dosing issues that 
could be useful for highlighting interventions to improve insulin adherence. 
CONCLUSIONS: No gold standard exists for measuring medication adherence in 
patients with diabetes. The plethora of adherence evaluation methods and 
different approaches to defining adherence/non-adherence precludes the 
comparison of adherence rates across studies. Greater consistency is therefore 
needed in adherence measurement, including question content, recall period, 
and response options for self-report measures, and definitions of “good 
adherence” for MPR. Novel methods for understanding adherence to variable-
dosed insulin require further research.  
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OBJECTIVES: Information on adherence among diabetes patient is rare in 
Bayelsa State, Niger Delta. The objective of the study was to determine the rate 
of adherence to therapy among diabetes mellitus patients. METHODS: It was a 
cross sectional survey with the use of an interviewer-administered 
questionnaire. A 4-item Morisky self-reported adherence scale in addition to 
other self-developed, validated and pretested questionnaires were used. This 
was administered to 263 patients receiving treatment at the Outpatient 
Department of the hospital after seeking and obtaining their consent between 
June and August 2012 on clinic days. Questions related to demographics, 
medication history, adherence rate, etc., were included. In addition, the 
respective case notes (263) of the same set of patients were examined, and 
relevant data extracted (such as blood glucose level). Data was appropriately 
analysed using SPSS. Descriptive statistics were used in presentation of results. 
RESULTS: Majority of the 210 patients (80.0%) were taking both metformin and 
glibenclamide tablets. About 60 percent, 156 (59.3%), of patients were adjudged 
adherent with prescribed medications on the 4-item Morisky scale of adherence 
with a score of 1.22±0.2, which differs significantly from the non-adherent group 
with a score of 3.34±0.87. (p<0.0001). However, overall adherences to all aspects 
of diabetes management were poorer as only 80 (30.5%) had normal fasting blood 
glucose level of less than 6.1mmol/l after at least five visits to the hospital. Only 
